Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
Phenomic will utilise its single-cell RNA transcriptomics programme to develop cancer therapies in collaborations with Astellas and Boehringer.
The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.
Prism Biolab is entitled to receive development and commercial milestone payments of up to $660m from Lilly.
With a target of net zero for 2050, pharmaceutical companies need to tackle scope 3 emissions, that make up the majority of their carbon footprint.
The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in SARS-CoV-2.
Give your business an edge with our leading industry insights.
The monoclonal antibody, approved to treat certain B-cell lymphomas, has received an FDA breakthrough therapy designation.
The expansion comes as Novo is trying to maintain strong growth in type 2 diabetes (T2D) after the launch of Eli Lilly’s Zepbound this month.
With more approved drugs coming through than ever before, the need to avoid confusing names to ensure patient safety is important.
Simcere will have the rights to develop and commercialise rademikibart in mainland China, Macau, Taiwan, and Hong Kong.
The warning letter issued to Cipla will further delay the launch timelines of the company’s Advair generic in the US.